Featured Research

from universities, journals, and other organizations

New lung cancer drug shows dramatic results for shrinking tumors: Phase III clinical trial being offered

Date:
June 23, 2010
Source:
University of California - San Diego
Summary:
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial being offered. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.

Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center. The new drug, crizotinib, under development by Pfizer, showed dramatic results in reducing lung cancer tumors in some patients during Phase I and II clinical trials.

Related Articles


"The results of the first two trials have been very encouraging," said Lyudmila Bazhenova, MD, assistant clinical professor at UC San Diego School of Medicine and a member of the Moores UCSD Cancer Center. "The Phase III clinical trials will be critical in determining if this drug goes to market."

According to a preliminary study presented at the 2010 meeting of the American Society of Clinical Oncology, Phase I/II clinical trials demonstrated that 57% of patients had their tumors reduced and at eight weeks of the treatment, 87% showed disease stabilization.

In some patients with non-small cell lung cancer (NSCLC), the anaplastic lymphoma kinase (ALK) gene may move and fuse with another gene, EML4. The resultant fusion produces an enzyme that promotes lung cancer cell growth. This fusion happens in approximately four percent of NSCLC patients. The chances of a patient having the fusion gene increases if they have the adenocarcinoma subtype of lung cancer, or are non-smokers or former light smokers, among other characteristics. Those patients have an approximate 20% chance of having this mutation. Crizotinib inhibits the enzyme, allowing the cancer cells to die off.

The Phase III clinical trial will compare crizotinib with standard-of-care chemotherapy in the treatment of ALK-positive recurrent NSCLC. Through a randomized selection process, patients will either be treated with chemotherapy or crizotinib. If the patients who are given the chemotherapy do not respond to treatment, they will be given crizotinib at the end of the trial.

Candidates for the Phase III trial must have stage four NSCLC and have gone through at least one round of chemotherapy. If the patient qualifies for the study, they will be tested for the gene at the Moores UCSD Cancer Center. Potential candidates for the clinical trial should call the clinical trials hotline at (858) 822-5354.

According to the American Cancer Society, more than 220,000 new lung cancer cases will be diagnosed in the U.S. in 2010. Only four percent of those cases will qualify for this clinical trial, which equals approximately 9,000 patients for whom this drug may help stop the growth of cancer.


Story Source:

The above story is based on materials provided by University of California - San Diego. Note: Materials may be edited for content and length.


Cite This Page:

University of California - San Diego. "New lung cancer drug shows dramatic results for shrinking tumors: Phase III clinical trial being offered." ScienceDaily. ScienceDaily, 23 June 2010. <www.sciencedaily.com/releases/2010/06/100622142603.htm>.
University of California - San Diego. (2010, June 23). New lung cancer drug shows dramatic results for shrinking tumors: Phase III clinical trial being offered. ScienceDaily. Retrieved November 22, 2014 from www.sciencedaily.com/releases/2010/06/100622142603.htm
University of California - San Diego. "New lung cancer drug shows dramatic results for shrinking tumors: Phase III clinical trial being offered." ScienceDaily. www.sciencedaily.com/releases/2010/06/100622142603.htm (accessed November 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, November 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com
Milestone Birthdays Can Bring Existential Crisis, Study Says

Milestone Birthdays Can Bring Existential Crisis, Study Says

Newsy (Nov. 21, 2014) Researchers find that as people approach new decades in their lives they make bigger life decisions. Video provided by Newsy
Powered by NewsLook.com
Ebola: Life Without School in Guinea

Ebola: Life Without School in Guinea

AFP (Nov. 21, 2014) Following the closure of schools and universities in Guinea because of the Ebola virus, students look for temporary work or gather in makeshift classrooms to catch up on their syllabus. Duration: 02:14 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins